Brittany M. Gouse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brittany M. Gouse has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Hannah E. Brown
Department of Psychiatry, Chobanian & Avedisian School of Medicine at Boston University, Boston, MA, USA
5 shared publications- Elijah E. Boliver
Wellness and Recovery After Psychosis Research Program, Department of Psychiatry, Boston Medical Center, Boston, MA, USA
3 shared publications - Sheryl Martin-Schild
Stroke Program, Department of Neurology, Tulane University School of Medicine, New Orleans, Louisiana
3 shared publications - Amelia C. Blanton
Wellness and Recovery After Psychosis Research Program, Department of Psychiatry, Boston Medical Center, Boston, MA, USA
2 shared publications Amelia K. Boehme
Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, NY; Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL
2 shared publicationsDominique J. Monlezun
Stroke Program, Department of Neurology, Tulane University Hospital, New Orleans, LA
2 shared publications
Latest Publications
- 16 September 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-11
A Pilot Feasibility Study of a Virtual Lifestyle Intervention for Individuals with Schizophrenia
Individuals with schizophrenia experience early mortality from physical health conditions. Lifestyle interventions are effective; however, barriers interfere with in-person program participation. This two-period randomized cross-over pilot study evaluated the feasibility and acceptability of a virtual lifestyle intervention in n = 19 individuals with schizophrenia. Secondary analyses explored outcome changes between intervention and control groups. Results indicated modest retention (58%) and intervention engagement (67%) for Period 1 (weeks 1–11) with especially low rates in Period 2 (weeks 12–22; retention: 37%, intervention engagement: 50%). Of participants with satisfaction data (n = 6), nearly all participants reported that the intervention was helpful and easy to follow. Secondary outcome changes during Period 1 favored the intervention group on nutritional knowledge, physical activity, mental health, physical health, exercise motivation, self-esteem, and weight/body mass index (Cohen’s ds: 0.35–2.09). Due to attrition and sparsity of data, neither a cross-over design analysis nor examination of outcome changes during Period 2 was conducted. Although satisfaction results and outcome changes from Period 1 were encouraging, the low rates of retention and intervention engagement in Period 2 raise feasibility concerns. Intervention development research is needed to determine whether modifications to this virtual lifestyle intervention would enhance feasibility and acceptability for people with schizophrenia.
- 16 September 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-11
A Pilot Feasibility Study of a Virtual Lifestyle Intervention for Individuals with Schizophrenia
Individuals with schizophrenia experience early mortality from physical health conditions. Lifestyle interventions are effective; however, barriers interfere with in-person program participation. This two-period randomized cross-over pilot study evaluated the feasibility and acceptability of a virtual lifestyle intervention in n = 19 individuals with schizophrenia. Secondary analyses explored outcome changes between intervention and control groups. Results indicated modest retention (58%) and intervention engagement (67%) for Period 1 (weeks 1–11) with especially low rates in Period 2 (weeks 12–22; retention: 37%, intervention engagement: 50%). Of participants with satisfaction data (n = 6), nearly all participants reported that the intervention was helpful and easy to follow. Secondary outcome changes during Period 1 favored the intervention group on nutritional knowledge, physical activity, mental health, physical health, exercise motivation, self-esteem, and weight/body mass index (Cohen’s ds: 0.35–2.09). Due to attrition and sparsity of data, neither a cross-over design analysis nor examination of outcome changes during Period 2 was conducted. Although satisfaction results and outcome changes from Period 1 were encouraging, the low rates of retention and intervention engagement in Period 2 raise feasibility concerns. Intervention development research is needed to determine whether modifications to this virtual lifestyle intervention would enhance feasibility and acceptability for people with schizophrenia.
- 30 July 2025
- Published by Hogrefe Publishing Group in Crisis
Suicidality Among Sexual or Gender Minority College Students With a Schizophrenia Spectrum Disorder
Background: Suicide is a leading cause of death among individuals with a schizophrenia spectrum disorder (SSD). Individuals who identify with a sexual and/or gender minority (SGM) identity are also at increased risk for suicidal thinking and behavior. Aims: To explore the association between SGM status and suicidality among university students with an SSD. Method: We used the 2019–2020 Healthy Minds survey data to explore the relationship between SGM status and past-year suicidal ideation, plan, and attempt among individuals with SSDs using bivariate and multivariable analyses. Results: Of 134 students with SSDs, 47.5% endorsed a sexual minority identity and 18.7% endorsed a gender minority identity. Gender minority individuals had 3.98 the odds of suicidal ideation compared to cisgender individuals (95% CI 1.16–13.60, p = .0277). There was no association between sexual minority identity and suicidal ideation. Limitations: This work was limited to a cross-sectional assessment using self-report survey data from a predominantly non-Latino White college student cohort, resulting in a small sample size and limited generalizability. Conclusion: The intersectionality of having a gender minority identity and an SSD may confer a heightened risk of suicidal ideation among young adults. University campuses and first-episode psychosis programs should consider targeted suicide prevention efforts in this population.
- 30 July 2025
- Published by Hogrefe Publishing Group in Crisis
Suicidality Among Sexual or Gender Minority College Students With a Schizophrenia Spectrum Disorder
Background: Suicide is a leading cause of death among individuals with a schizophrenia spectrum disorder (SSD). Individuals who identify with a sexual and/or gender minority (SGM) identity are also at increased risk for suicidal thinking and behavior. Aims: To explore the association between SGM status and suicidality among university students with an SSD. Method: We used the 2019–2020 Healthy Minds survey data to explore the relationship between SGM status and past-year suicidal ideation, plan, and attempt among individuals with SSDs using bivariate and multivariable analyses. Results: Of 134 students with SSDs, 47.5% endorsed a sexual minority identity and 18.7% endorsed a gender minority identity. Gender minority individuals had 3.98 the odds of suicidal ideation compared to cisgender individuals (95% CI 1.16–13.60, p = .0277). There was no association between sexual minority identity and suicidal ideation. Limitations: This work was limited to a cross-sectional assessment using self-report survey data from a predominantly non-Latino White college student cohort, resulting in a small sample size and limited generalizability. Conclusion: The intersectionality of having a gender minority identity and an SSD may confer a heightened risk of suicidal ideation among young adults. University campuses and first-episode psychosis programs should consider targeted suicide prevention efforts in this population.
- 10 April 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 267, 301-307
COVID-19 pandemic and emergency department visits for psychosis: Visit volume, restraint use, medication use, psychiatric hospitalization, and length of stay
- 10 April 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 267, 301-307
COVID-19 pandemic and emergency department visits for psychosis: Visit volume, restraint use, medication use, psychiatric hospitalization, and length of stay
- 20 April 2023
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 17 (12) , 1207-1215
Demographic predictors of lack of current mental health treatment among university students with a schizophrenia spectrum disorder
AimTo identify the demographic predictors of lack of current mental health (MH) treatment among university students with a schizophrenia spectrum disorder (SSD). MethodsAdult university students with a self-identified diagnosis of an SSD (schizophreniform, schizophrenia, schizoaffective disorder) were identified from the 2019-2020 Healthy Minds Study survey. In this study, pertinent demographic factors included age, race/ethnicity, sex assigned at birth, gender identity, sexual orientation, parental education, financial stress, and employment. Multivariable modelling was used to investigate the demographic predictors of lack of current psychotherapy treatment, no current antipsychotic use, and lack of any MH treatment (defined as concurrent lack of psychotherapy and antipsychotic treatment). ResultsOf the 135 included students with a SSD, the median age was 23 years old and 79 (58.5%) were assigned female at birth. Fifty-five participants (40.7%) lacked any current MH treatment. In fully adjusted models, lack of current MH treatment was associated with working more than 20 h per week (OR 2.9 [1.2-7.1], p = 0.02). No current antipsychotic use was associated with Hispanic/Latino race/ethnicity (OR 4.2 (1.2-14.5), p = 0.04). Lack of current psychotherapy treatment was associated with cisgender male identity (OR 5.5 [2.0-15.2], p < 0.01), working greater than 20 hours per week (OR 6.5 [2.2-19.2], p < 0.01), and having one or more structural or attitudinal barriers to care (OR = 4.6 [1.5-13.9], p < 0.01). ConclusionsThe demographic predictors of lack of current MH treatment varied between psychotherapy and antipsychotic use, suggesting university health centres should consider interventions targeting several at-risk populations to increase treatment use among students with a SSD.
- 20 April 2023
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 17 (12) , 1207-1215
Demographic predictors of lack of current mental health treatment among university students with a schizophrenia spectrum disorder
AimTo identify the demographic predictors of lack of current mental health (MH) treatment among university students with a schizophrenia spectrum disorder (SSD). MethodsAdult university students with a self-identified diagnosis of an SSD (schizophreniform, schizophrenia, schizoaffective disorder) were identified from the 2019-2020 Healthy Minds Study survey. In this study, pertinent demographic factors included age, race/ethnicity, sex assigned at birth, gender identity, sexual orientation, parental education, financial stress, and employment. Multivariable modelling was used to investigate the demographic predictors of lack of current psychotherapy treatment, no current antipsychotic use, and lack of any MH treatment (defined as concurrent lack of psychotherapy and antipsychotic treatment). ResultsOf the 135 included students with a SSD, the median age was 23 years old and 79 (58.5%) were assigned female at birth. Fifty-five participants (40.7%) lacked any current MH treatment. In fully adjusted models, lack of current MH treatment was associated with working more than 20 h per week (OR 2.9 [1.2-7.1], p = 0.02). No current antipsychotic use was associated with Hispanic/Latino race/ethnicity (OR 4.2 (1.2-14.5), p = 0.04). Lack of current psychotherapy treatment was associated with cisgender male identity (OR 5.5 [2.0-15.2], p < 0.01), working greater than 20 hours per week (OR 6.5 [2.2-19.2], p < 0.01), and having one or more structural or attitudinal barriers to care (OR = 4.6 [1.5-13.9], p < 0.01). ConclusionsThe demographic predictors of lack of current MH treatment varied between psychotherapy and antipsychotic use, suggesting university health centres should consider interventions targeting several at-risk populations to increase treatment use among students with a SSD.
- 1 July 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (7) , e2224172
Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness
The reduction of adverse outcomes is of crucial importance in schizophrenia, a relapsing and remitting chronic illness with a 13- to 15-year reduction in life e
- 1 July 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (7) , e2224172
Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness
The reduction of adverse outcomes is of crucial importance in schizophrenia, a relapsing and remitting chronic illness with a 13- to 15-year reduction in life e
- 1 October 2020
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 89, 529-530
Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism
- 1 October 2020
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 89, 529-530
Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 77 (6) , 650-651
Effect Size and Blinding in Lumateperone Trial
To the Editor The article “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial”1 by Correll and colleagues was notable for its thorough data analyses (including multiple sensitivity analyses of the primary outcome) and for the relatively low rate of both negative metabolic effects and extrapyramidal symptoms observed with lumateperone. These 2 classes of adverse events have been associated with treatment nonadherence in this vulnerable patient population.2
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 77 (6) , 650-651
Effect Size and Blinding in Lumateperone Trial
To the Editor The article “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial”1 by Correll and colleagues was notable for its thorough data analyses (including multiple sensitivity analyses of the primary outcome) and for the relatively low rate of both negative metabolic effects and extrapyramidal symptoms observed with lumateperone. These 2 classes of adverse events have been associated with treatment nonadherence in this vulnerable patient population.2
- 1 March 2015
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 24 (3) , 680-686
A Simple Prediction Score for Developing a Hospital-Acquired Infection after Acute Ischemic Stroke
- 1 March 2015
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 24 (3) , 680-686
A Simple Prediction Score for Developing a Hospital-Acquired Infection after Acute Ischemic Stroke